TABLE 2.
Outcomes after 6 and 12 months of treatment
| Baseline | T6 | T12 | p | |
|---|---|---|---|---|
| Exacerbations, mean ± SD | 5.0 ± 3.4 | 0.3 ± 0.7 | 0.2 ± 0.5 | <.01 |
| Patients (n) | 160 | 134 | 49 | |
| OCS (prednisone eq.), mg/day, Median(IQR) | 5.0 (0.0–12.5) | 0.0 (0.0–0.0) | 0.0 (0.0–0.0) | <.01 |
| Patients on OCS (n)* | 95/160 | 24/126 | 4/47 | |
| Pre‐bronchodilator FEV1 | ||||
| ‐ L, mean ± SD | 1.83 ± 0.8 | 2.3 ± 0.8 | 2.25 ± 0.7 | <.01 |
| ‐ %, mean ± SD | 65.6 ± 21.1 | 79.3 ± 21.5 | 76.3 ± 17.8 | |
| Patients (n) | 160 | 103 | 44 | |
| ACT, mean ± SD | 13.6 ± 4.1 | 20.8 ± 4.1 | 21.6 ± 3.3 | <.01 |
| Patients (n) | 160 | 118 | 49 | |
| AQLQ, mean ± SD | 3.4 ± 1.1 | 5.6 ± 1.1 | 5.9 ± 1.0 | <.01 |
| Patients (n) | 160 | 82 | 35 | |
| SNOT 22, mean ± SD | 49.4 ± 19.7 | 34.2 ± 20.5 | 23.5 ± 16.9 | NS |
| Patients (n) | 70 | 63 | 8 | |
| FeNO (ppb), median (IQR) | 45 (24.5, 62.5) | 25.5 (15.0, 41.0) | 25.0 (18.0, 65.0) | <.01 |
| Patients (n) | 80 | 46 | 30 | |
| Eosinophils (cells/μl), median (IQR) | 0.69 (0.46, 0.97) | 0 (0, 0) | 0 (0, 0) | <.01 |
| Patients (n) | 160 | 115 | 44 | |
Abbreviations: ACT, Asthma control test; AQLQ, Asthma quality of life questionnaire; denominator: patients observed at each specific time‐point; FeNO, Fractional exhaled nitric oxide. To compare the 3 measurements in T0, T6 and T12, the Friedman test was used. *numerator: patients for whom the data are available; FEV1, Forced expiratory volume in 1 second; IQR, Interquartile range; OCS, Oral corticosteroids; SD, Standard deviation; SNOT‐22, Sino‐nasal outcome test.